Issue 46 - Dec 15, 2017
  • “We’re gonna free the data,” Sharpless pledges at NCI Town Hall

    In his first talk to  NCI staff, director Norman “Ned” Sharpless presented himself as an institute insider—highlighting his career-long relationships with NCI and its “legends,” demonstrating his grasp of the institute’s agenda and research portfolio.

  • Five health systems join Strata Oncology network to sequence and match patients to targeted therapy trials

    Five health care systems have joined a precision oncology network that sequences patients’ tumors at no cost and matches patients to clinical trials.

  • As FDA, AHRQ spar over incidence estimates for uterine sarcomas, FDA reiterates recommendation to restrict power morcellation

    About one in 225 to one in 580 women who undergo surgery for fibroids may have hidden uterine cancers, FDA concluded in a recent review of medical studies published over the past four years.

    The updated estimate is generally consistent with one contained in the agency’s 2014 review, FDA officials said in a statement Dec. 14. Three years ago,  the agency estimated that  one in 350 women undergoing such surgery may have a previously undiagnosed sarcoma.

  • Anticipating fundamental change in oncology

    In 2017, The Cancer Letter’s readership grew by over 40 percent and the number of page views has nearly doubled from the 2016 level.

    On an average day in 2017, our website got over 1,700 visits and over 12,500 page views. By way of comparison, in 2016, we gauged 1,200 visits and 6,800 page views. We are losing the right to call ourselves a small publication.

  • In Brief

    • AACR urges House-Senate conference to remove tax bill provisions penalizing future scientists, patients, survivors
    • 2017 AACR-Bayer Innovation and Discovery Grants recipients announced
    • USPSTF recommends against hormone therapy for preventing chronic conditions 
    • Jason Incorvati joins hem/onc department at New Fox Chase East Norriton Campus
  • Drugs and Targets

    • Fate Therapeutics completes technology transfer and starts IND-enabling manufacture of FT500
Issue 45 - Dec 8, 2017
  • Building a “hybrid” center by the Beltway, Trump pursues vision of a new national research network

    As he goes about the task of building a cancer center, Donald “Skip” Trump has to align the money, the real estate, the recruitment—all the customary components of an institution.

    Sure, all of this is more complex because Trump is building the Inova Schar Cancer Institute in hyper-competitive and wealthy Northern Virginia, literally by the outer loop of the Beltway.

  • FDA considers using data from approved indications to support regular approvals of sNDAs based on intermediate endpoints

    FDA officials are floating a proposal for a review process informally dubbed “reverse accelerated approval.”

    This mechanism would come into play in situations where the data that have already been provided to the agency may justify approval of supplemental indications.

  • Guest Editorial

    Tobacco companies finally have to say smoking causes cancer

    These statements may not be breaking news for oncologists and other physicians, who should have been aware of the lethal nature of cigarette smoking at least since the publication of the first Surgeon General’s report on Smoking and Health more than half a century ago.

  • In Brief

    • William Oh named deputy director of Tisch Cancer Institute
    • Pisters embarks on “listening tour” at MD Anderson
    • Viviane Tabar named chair of the department of neurosurgery at MSK
    • Aradhana Ghosh named vice president of oncology at Syapse
    • NCI awards $16 million grant to PHSU and Moffitt to strengthen tissue bank, reduce health disparities
    • New national clinical trial investigated link between diabetes and pancreatic cancer
    • Mount Sinai’s Sundar Jagannath wins MMRF award
    • AACR urges Congress to reach bipartisan budget agreement
  • Drugs and Targets

    • FDA grants Avastin full approval for glioblastoma
Issue 44 - Nov 28, 2017
  • Caligiuri named president of City of Hope National Medical Center

    Michael Caligiuri was named physician-in-chief of City of Hope and president of City of Hope National Medical Center.

    Caligiuri recently stepped down as director of The Ohio State University Comprehensive Cancer Center and as CEO of the Arthur G. James Cancer Hospital and Richard J. Solove Research Institute.

    He will join City of Hope in this newly created position next February. The appointment was announced on Nov. 28.

  • Conversation with the Cancer Letter

    Caligiuri: It was time for me to hit the refresh button on my career

    After 20 years at Ohio State University, Michael Caligiuri is moving on.

    Caligiuri was named physician-in-chief of City of Hope and president of City of Hope National Medical Center on Nov. 28. He stepped down as director of The Ohio State University Comprehensive Cancer Center and as CEO of the Arthur G. James Cancer Hospital and Richard J. Solove Research Institute earlier this month.

  • NCI Director’s Report

    Sharpless lists initial priorities for NCI: Big Data, cell therapy, and more trials at the NIH Clinical Center

    NCI needs to focus on developing a structured approach to Big Data initiatives to ensure optimal use of the institute’s limited resources, said NCI Director Norman “Ned” Sharpless at his first joint meeting of the National Cancer Advisory Board and the Board of Scientific Advisors.

  • FDA approves Foundation Medicine’s genomic profiling test for all solid tumors; CMS proposes coverage

    FDA has approved the FoundationOne CDx, the first breakthrough-designated, next generation sequencing-based in vitro diagnostic test that can detect genetic mutations in 324 genes and two genomic signatures in any solid tumor type.

    The Centers for Medicare & Medicaid Services—at the same time—proposed coverage of the F1CDx, a laboratory-developed test sponsored by Foundation Medicine.

  • In Brief

    • FDA’s Pazdur named to Bloomberg 50 list
    • National Academies report calls for government negotiation of drug prices
    • Antonio Wolff named chair of ECOG-ACRIN Breast Cancer Committee
    • Louis Weiner to lead MedStar Georgetown Cancer Institute
    • LLS awards $5 million grant to team led by Sylvester’s Stephen Nimer
    • Ronda Henry-Tillman named to Kohn Chair in breast surgical oncology UAMS
    • NCCN, in collaboration with Pfizer, awards nine grants for quality improvement in breast cancer
    • Ronald Maier elected president of American College of Surgeons
    • Leigh Neumayer elected chair of the ACS board of regents
  • Drugs and Targets

    • FDA approves Ogivri, first biosimilar for treating breast and stomach cancers
    • Tesaro receives European approval of Zejula for recurrent ovarian cancer
    • G1 Therapeutics and AstraZeneca enter clinical trials collaboration in NSCLC
    • ITUS Corp. Moffitt enter into CRADA to develop CAR-T technology